

Name: Paul D. Ling, Ph.D.

Current Position: Associate Professor (Tenured)
Department of Molecular Virology and Microbiology
Baylor College of Medicine
One Baylor Plaza
Houston, Texas 77030

Education/training

1984 B.A., St. Olaf College, Northfield, MN
Field: Chemistry

1990 Ph.D., Uniformed Services University of the Health Sciences, Bethesda, MD
Field: Microbiology

1995 Postdoctoral Fellowship, Johns Hopkins School of Medicine, Baltimore, MD
Field: Virology/Cancer

Previous positions

5/1983–9/1983 Undergraduate research summer fellowship for Dr. Mike Iverson, Department of Pathology, Yale University, New Haven, CT.

8/1985–6/1990 Graduate Student for Dr. John Hay, Professor, Department of Microbiology, Uniformed Services University of the Health Sciences, Bethesda, MD.

7/1990–7/1993 Postdoctoral fellow for Dr. Diane Hayward, Associate Professor, Department of Pharmacology, Johns Hopkins Medical School, Baltimore, MD.

7/1993–10/1994 Research Associate, Department of Pharmacology and Molecular Sciences, Johns Hopkins Medical School, Baltimore, MD.

11/1994–5/2004 Assistant Professor, Division of Molecular Virology, Baylor College of Medicine, Houston, Texas

Honors

1984 Graduated Cum Laude, St. Olaf College

1991–1993 National Research Service Award for individual postdoctoral fellows

1994–1997 Leukemia Society of America Special Fellow Award

2006–2013 Secretary, Epstein-Barr virus association

2009–2013 Member, American Cancer Society peer review group (MPC)

2011 Certificate of Appreciation, Elephant Managers Association (EMA)

2013–present Chair, American Cancer Society peer review group (MPC)

2013–present Associate Editor, *PLOS Pathogens*

2014–present Elephant Endotheliotropic Herpesvirus (EEHV) Advisory Committee

Peer-reviewed publications

Ling, P.D., Warren, M.K., and Vogel, S.N. 1985. Antagonistic Effect of Interferon- β on the Interferon- γ -induced Expression of Ia antigen in Murine Macrophages. *J. Immunology*. 135: 1857-1863.

Kinchington, P.R., Ling, P., Ruyechan, W.T., and Hay, J. 1990. The glycoprotein products of varicella-zoster virus gene 14 and their defective accumulation in a vaccine strain (Oka). *J. Virol.* 64: 4540-4548.

- Kinchington, P.R., Ling, P., Pensiero, M., Gershon, A., Hay, J., and Ruyechan, W.T. 1990. A possible Role for Glycoprotein gpV in the Pathogenesis of Varicella Zoster Virus. *Adv Exp Med Biol.* 1990: 83-91.
- Ling, P., Kinchington, P.R., Ruyechan, W.T., and Hay, J. 1991. A Detailed Analysis of Transcripts Mapping to Varicella-Zoster Virus Gene 14 (Glycoprotein V). *Virology* 184:625-635.
- Ling, P., Kinchington, P.R., Ruyechan, W.T., and Hay, J. 1992. Transcription from Varicella-Zoster Virus Gene 67 (Glycoprotein IV). *J. Virol.* 66:3690-3698.
- Lowry P.W., Solem, S., Watson, B.N., Koropchak, C.M., Thackray, H.M., Kinchington P.R., Ruyechan W.T., Ling, P., Hay, J., and A.M. Arvin 1992. Immunity in strain 2 guinea pigs inoculated with vaccinia recombinants expressing varicella-zoster virus glycoproteins I, IV, V or the protein product of the immediate early gene 62. *J. Gen. Virol.* 73:811-819.
- Ling, P.D., Ryon, J.R., and Hayward, S.D. 1993. EBNA-2 of Herpesvirus Papio diverges significantly from the type A and type B EBNA-2 proteins of Epstein Barr virus but retains an efficient transactivation domain with a conserved hydrophobic motif. *J. Virol.* 67: 2990-3003.
- Ling, P.D., Rawlins, D.R., and Hayward, S.D. 1993. The EBV immortalizing protein EBNA-2 is targeted to DNA by a cellular enhancer-binding protein. *PNAS* 90:9237-9241.
- Ling, P.D., Hsieh, J-D., Ruf, I.K., Rawlins, D.R., and Hayward, S.D. 1994. EBNA2 Upregulation of Epstein-Barr Virus Latency Promoters and the Cellular CD23 Promoter Utilizes a Common Targeting Intermediate, CBF1. *J. Virol.* 68:5375-5383.
- Henkel, T., Ling, P.D., Hayward, S.D, and Peterson, M.G.. 1994. Mediation of Epstein Barr Virus EBNA2 Transactivation by Recombination Signal-Binding Protein Jk. *Science* 265:92-95.
- Ling, P.D. and Hayward, S.D. 1995. Contribution of Conserved Amino Acids in Mediating Interaction between EBNA2 and CBF1/RBPJk. *J. Virol.*, 69:1944-1950.
- Robertson, K.D., Hayward, S.D., Ling, P.D., Samid, D., and Ambinder, R.F. 1995. Transcriptional activation of the EBV latency C promoter following 5-azacytidine treatment: Evidence that demethylation at a single CpG site is crucial. *Mol. Cell. Biol.* 15:6150-6159.
- Fuentes-Pananá, E.M. and Ling, P.D. 1998. Characterization of the CBF2 binding site within the Epstein-Barr virus latency C Promoter and its role in modulating EBNA2-mediated transactivation. *J. Virol.* 72:693-700.
- Fuentes-Pananá, E.M., Swaminathan, S., and Ling, P.D. 1999. Transcriptional activation signals found in the Epstein-Barr virus (EBV) latency C promoter are conserved in the latency C promoter sequences from baboon and rhesus monkey EBV-like lymphocryptoviruses (cercopithecine herpesviruses 12 and 15). *J. Virol.* 73:826-833.
- Cho, Y. G., Gordadze, A. V., Ling, P. D. and F. Wang. 1999. Evolution of two types of Rhesus Lymphocryptovirus to similar type 1 and type 2 Epstein-Barr virus. *J. Virol.* 73: 9206-9212.
- Peng, R. S., Gordadze, A. G., Fuentes-Pananá, E. M., Wang, F., Zong, J., Hayward, G. S., Tan, J., and P. D. Ling. 2000. Sequence and functional analysis of EBNA-LP and EBNA2 proteins from nonhuman primate lymphocryptoviruses. *J. Virol.* 74: 379-389.
- Fuentes Pananá, E. M., Peng, R. S., Brewer, G., Tan, J., and P. D. Ling. 2000. Regulation of the Epstein-Barr virus C promoter by AUF1 and the cAMP/PKA signaling pathway. *J. Virol.*, 74: 8166-8175.
- Peng, R. S., Tan, J., and P. D. Ling. 2000. Conserved regions in the Epstein-Barr Virus leader protein define distinct domains required for nuclear localization and transcriptional cooperation with EBNA2. *J. Virol.*, 74: 9953-9963.

- Gordadze, A. V., Peng, R.S., Tan, J., Liu, G.Z., Sutton, R., Kempkes, B., Bornkamm, G.W., and P. D. Ling. 2001. Notch1IC partially replaces EBNA2 function in B cells immortalized by Epstein-Barr virus. *J. Virol.* 75:5899-5912.
- Savoldo B, Cabbage ML, Durett AG, Goss J, Huls MH, Liu Z, Teresita L, Gee AP, Ling PD, Brenner MK, Heslop HE, and Rooney CM. 2002. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. *J. Immunol.* 168:909-918.
- O'Sullivan, C., Peng, R.S., Jenson, H., and Ling, P.D. 2002. Epstein-Barr virus genome loads in the peripheral blood and antibody titers to EBV antigens in AIDS patients before and after HAART therapy. *J. Med. Virol.* 67:320-326.
- Gordadze, A.V., Poston, D., and Ling, P.D. 2002. The EBNA2 Polyproline region is dispensable for Epstein-Barr virus-mediated immortalization maintenance. *J. Virol.* 76:7349-7355.
- Ling, P.D., Lednicky, J.A., Keitel, W.A., Poston, D.A., White, Z.S., Peng R.S., Mehta, S.K., Pierson, D.L., Vilchez, R.A., Smith, E.O., and Janet S. Butel. 2003. The Dynamics of Herpesvirus and Polyomavirus Reactivation and Shedding in Healthy Adults: A 14-Month Longitudinal Study. *JID* 187:1571-80.
- Walling, D. M., Brown A. L., Etienne W., Keitel, W. A., and P. D. Ling. 2003. Multiple EBV infections in healthy individuals. *J. Virol.* 77:6546-6550.
- Ling P.D., Vilchez, R.A., Keitel, W.A., Poston, D.A., Peng, R.S., White, Z.S., Visnegarwala, F., Kozinetz, C.A., Lewis, D., and Janet S. Butel. 2003. Epstein-Barr Virus DNA Loads in Adult HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy. *Clin. Infec. Dis.* 37:1244-1249.
- Gordadze, A.V., Onunwor, C.W., Peng, R.S., Kremmer, E., and P.D. Ling. 2004. EBNA2 amino acids 2-30 are required for induction of LMP-1 and immortalization maintenance. *J. Virol.* 78:3919-3929.
- Walling, D.M., Ling, P.D., Gordadze, A.V., Walters-Montes, M., Flaitz, C.M., and C.M. Nichols. 2004. EBV Gene Expression in Hairy Leukoplakia. *JID* 190:396-399.
- Lee, J.M., Lee K.H., Farrell, C.J., Ling P.D., Kempkes, B., Park, J.H., and S.D. Hayward. 2004. EBNA2 is required for protection of latently Epstein-Barr virus infected B cells against specific apoptotic stimuli. *J. Virol.* 78:12694-12697.
- Peng, R.S., Moses, S.M., Tan J.T., Kremmer, E., and P.D. Ling. 2005. The Epstein-Barr virus EBNA-LP protein preferentially co-activates EBNA2-mediated stimulation of latent membrane proteins expressed from the viral divergent promoter. *J. Virol.* 79:4492-4505.
- Ling, P. D., and H. H. Huls. 2006. Isolation and Immortalization of Lymphocytes. *In* F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, and K. Struhl (ed.), *Current protocols in Molecular Biology*. John Wiley & Sons, Inc.
- Ling, P.D., Peng, R.S., Nakajima, A., Yu, J.H., Tan, J., Moses, S.C., Yang, W-H., Zhao, B., Kieff, E., Bloch, K.D., and D.B. Bloch. 2006. Mediation of Epstein-Barr virus EBNA-LP transcriptional coactivation by the PML nuclear body-associated protein Sp100. *EMBO J.* 24:3565-3575.
- Echendu, C.W. and P. D. Ling. 2008. Epstein-Barr virus EBNA-LP function is refractory to the effects of type I interferons. *J. Cytokine and Interferon Res.* 28: 667-678.
- Ling, P. D., Tan, J., Sewatanon, J., and R.S. Peng. 2008. The murine gammaherpesvirus 68 ORF75c tegument protein induces the degradation of PML and is essential for production of infectious virus. *J. Virol.* 82: 8000-8012.
- Ling, P. D., Tan, J., and R.S. Peng. 2009. Nuclear-cytoplasmic shuttling is not required for EBV EBNA-LP coactivation function. *J. Virol.* 83:7109-7116.

- Stanton, J.J., Zong, J.C., Latimer, E., Tan, J., Herron, A., Hayward, G.S., and P.D. Ling. 2010. Detection of Pathogenic Elephant Endotheliotropic Herpesvirus in Routine Trunk Washes from Healthy Adult Asian Elephants (*Elephas maximus*) using a Novel Quantitative Real-Time PCR Assay. *AJVR*. 71: 925-933.
- Kim, YE, Lee JH, Kim ET, Gu SY, Seol HS, Ling, PD, Lee CH, and Ahn JH. 2011. Human Cytomegalovirus infection causes degradation of Sp100 proteins that suppress viral gene expression. *J. Virol*. 85:11928
- Ramakrishnan R., Donahue, H., Garcia, D., Tan, J., Shimizu, N., Rice, A.P., and P.D. Ling. 2011. Epstein-Barr virus BART9 miRNA modulates LMP1 levels and affects growth rate of Nasal NK T cell lymphomas. *Plos One*. 6(11) e27271.
- Stanton, J.J., Nofs, S., Peng, R.S., Hayward, G.S., and P. D. Ling. 2012. Development and Validation of Quantitative Real-time Polymerase Chain Reaction Assays to Detect Elephant Endotheliotropic Herpesviruses-2, 3, 4, 5, and 6. *J. Virological Methods* 186:73-77.
- Stanton, J.J., Zong, J.C., Eng, C., Howard, L., Flanagan, J., Stevens, M., Schmitt, D., Wiedner, E., Graham, D., Junge, R.E., Weber, M.A., Fischer, M., Mejia, A., Tan, J., Latimer, E., Herron, A., Hayward, G.S., and P.D. Ling. 2013. Kinetics of Viral Loads and Genotypic Analysis of Elephant Endotheliotropic Herpesvirus-1 Infection in Captive Asian Elephants (*Elephas Maximus*). *J. Zoo and Wildlife Medicine* 44:42-54.
- Atkins, L, Zong, J.C., Tan, J., Mejia, A., Heaggans, S.Y., Nofs, S., Stanton, J.J., Flanagan, J.P., Howard, L., Latimer, E., Stevens, M.R., Hoffman, D.S., Hayward, G.S., and Paul D. Ling. 2013. Elephant Endotheliotropic herpesvirus 5, a newly recognized elephant herpesvirus associated with clinical and subclinical infections in captive Asian elephants (*Elephas Maximus*). *J. Zoo and Wildlife Medicine* 44:136-143.
- Sewatanon, J., and P. D. Ling. 2013. Murine gammaherpesvirus 68 ORF75c contains ubiquitin E3 ligase activity and requires PML SUMOylation but not other known PML regulators, CK2 or E6AP, to mediate PML degradation. *Virology* 440: 140-149
- Nofs, S., Stanton, J.J., Hanlon, C., Tan, J., Flannagan, J.P., Howard, L., and P.D. Ling. 2013. Prenatal passive transfer of Maternal Immunity in Asian Elephants (*Elephas Maximus*). *Veterinary Immunology and Immunopathology* 153: 308-311.
- Ling, P.D., Reid, J.G., Qin, X., Muzny, D.M., Gibbs, R., Petrosino, J., Peng, RS, Zong, JC, Heaggans S.Y., and Gary S. Hayward. 2013. The Complete Genome Sequence of Elephant Endotheliotropic Herpesvirus 1A (EEHV1A). *Genome Announc* 1:e0004913.
- Stanton J.J., Cray, C.C., Dickey, M., Rodriguez, M., Arheart, K.L., Ling, P.D., and A. Herron. 2013. Acute Phase protein expression during elephant endotheliotropic herpesvirus viremia in Asian elephants (*Elephas Maximus*). *J. Zoo and Wildlife Medicine* 44:605-613.
- Sewatanon, J., Liu, H., and P. D. Ling. 2013. PML protein modulates establishment and maintenance of latent g-Herpesvirus Infection in Peritoneal cells. *J. Virol*. 87:12151-12157.
- Sewatanon, J., and P. D. Ling. 2014. MHV68 encodes a second PML-modifying protein. *J. Virol*. 88(6): 3591-3597.
- Stanton, J.J., Nofs, S., Zachariah, A., Kalaivannan, N., and P.D. Ling. 2014. Detection of elephant endotheliotropic herpesvirus infection amongst healthy Asian elephants (*Elephas Maximus*) in South India using real-time polymerase chain reaction assays. *J. Wildlife Diseases* 50(2): 279-287.
- Humphreys, A.F. Tan, J., Peng, RS, Benton, S.M., Qin, X., Worley, K.C., Mikulski, R.L., Chow, D-C., Palzkill, T.G., and P.D. Ling. 2015. Generation and characterization of antibodies against Asian elephant (*Elephas maximus*) IgG, IgM, and IgA. *PLoS ONE* 10(2): e0116318.

Friberg, A., Thumann, S., Hennig, J., Zou, P., Ling, P.D., Sattler, M., Kempkes, B. 2015. Structural basis for dimerization of EBNA-2 and target gene activation. (**Submitted, Plos Pathogens**)

Book Chapters

Ruyechan, W.T., Ling P.D., Kinchington, P.R., and Hay, J. 1990. "The Correlation Between Varicella-Zoster Virus Transcription and the Sequence of the Viral Genome"., In *Herpesvirus Transcription and its Regulation*. (E.K. Wagner, ed.) CRC Press, Boca Rotan, FL. Pp. 301-317.

Ling, P. D., and H. H. Huls. 2005. Isolation and Immortalization of Lymphocytes. *In* F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, and K. Struhl (ed.), *Current protocols in Molecular Biology*. John Wiley & Sons, Inc.

Ling, P. D. 2010. EBNA-LP Function. In *Epstein-Barr virus latency and transformation*, E.S. Robertson (ed), Horizon Press.

Kempkes, B. and P. D. Ling. 2015. EBNA2 and its coactivator EBNA-LP. In *Epstein –Barr virus: one virus-many diseases*. C. Munz (ed), Springer.